Skip to content
PaperFren

Research method

Cross-Sectional Survey

A cross-sectional survey measures exposures and outcomes at one time — or as repeated snapshots of different people — rather than following the same cohort to incident events. The usual products are prevalence, coverage, hypothetical acceptance, or utilisation counts. Because exposure and outcome are contemporaneous, the design cannot by itself establish that one caused the other, and a convenience or telephone sample can mis-rank who would actually take up a vaccine.

Vaccination and service papers reach for surveys when they need a population percentage now: who would accept a COVID vaccine at 90% efficacy, who received seasonal versus pandemic influenza vaccine, who used telemedicine this year. It answers 'how common is this in this sample at this moment?' Its main limitation is that 79.6% hypothetical acceptance is not 79.6% later uptake, administrative visit counts are not care quality, and a cluster-randomised trial that happens to use community questionnaires is not 'just a survey.'

Studies

4

Findings

4

4 supporting · 0 challenging · 0 qualifying citations

Open tensions

1

Currently

What we know

  1. A Libyan survey of 15,087 respondents found COVID-19 vaccine acceptance of 79.6% if efficacy were ≥90%, 60.6% if ≥70%, and 41.2% if 50%. Most respondents were general public; about one-quarter were students or clinicians. Convenience/online sampling and hypothetical efficacy scenarios limit inference about later real uptake.
  2. A retrospective telephone survey estimated seasonal influenza coverage at about 20.6–20.8% overall and about 55% among at-risk people, versus 11.1% overall for the 2009 pandemic vaccine. Older adults had high seasonal but low pandemic uptake. Self-report and incomplete household response can bias those percentages; cross-sectional correlates of uptake are not causal.
  3. Repeated administrative snapshots of rural telemedicine in Ontario are sometimes filed with surveys even though nobody filled a questionnaire. Users rose from 14,666 (1.4%) in earlier years to 290,401 (28.1%) in the first half of 2020 as COVID-era fee codes broadened virtual visits. Pre-pandemic use concentrated in Northern Ontario and younger adults; during COVID, use broadened geographically, skewed female, rose with age, and surged in urban as well as rural areas. Utilisation is not clinical quality or safe substitution for needed exams.
  4. SASA! used community surveys as outcome tools inside a cluster-randomised trial in Kampala, not as a stand-alone cross-section. Past-year physical IPV and men's concurrency were about 50% lower in intervention communities, with improved attitudes toward women's right to refuse sex. Wide CIs on some IPV estimates and election-period interruption still apply; the randomisation, not the questionnaire format, is what supports a causal reading.

Largest unresolved question

Hypothetical acceptance, reported coverage, administrative utilisation and CRT endline surveys are four different measurement jobs. Libya's 79.6% at ≥90% efficacy is a stated intention under a scenario. Seasonal flu coverage of ~21% and pandemic coverage of 11.1% are recalled past behaviour. Telemedicine's jump from 1.4% to 28.1% is billing data. SASA!'s ~50% IPV contrast is a randomised community comparison that used surveys. Averaging those percentages as 'survey findings on uptake' erases the disagreements.

Common misconceptions

  • If 79.6% say they would accept a ≥90% efficacious COVID vaccine, about 80% will be vaccinated.

    That figure is hypothetical acceptance in an online/convenience sample of 15,087, and it falls to 60.6% at ≥70% efficacy and 41.2% at 50%. Intention precedes uptake, and the sampling frame is not a probability sample of later programmes.

  • Older adults' high seasonal flu coverage means they also took up pandemic vaccine, so age is a stable 'vaccine-positive' trait.

    The telephone survey found about 55% seasonal coverage among at-risk people and high seasonal uptake in older adults, but pandemic coverage was 11.1% overall with low pandemic uptake in that same older group. Cross-sectional correlates can reverse across products.

  • SASA! is a one-time survey showing Kampala had 50% less IPV, and telemedicine user counts prove virtual care was better.

    SASA! cluster-randomised communities and then surveyed them; the ~50% IPV and concurrency contrasts are intervention effects with wide CIs on some estimates. Telemedicine snapshots show 14,666 to 290,401 users (1.4% to 28.1%), not quality, equity of outcomes, or safe replacement of exams.

Related